BeiGene Ltd

**Policy Advocacy**

BeiGene also regularly engages with policymakers in support of our mission to provide high-quality, affordable medicines to patients. We follow international governance guidelines and country-specific regulations and laws such as the Lobbying Disclosure Act in the U.S., to ensure proper interactions with government officials. In 2020, BeiGene did not make any corporate political donations.

###### Advocacy

BeiGene regularly engages with policymakers in support of our mission to provide high-quality, affordable medicines to patients. We follow international governance guidelines and country-specific regulations and laws, such as the Lobbying Disclosure Act in the U.S., to ensure proper interactions with government officials. In 2021, BeiGene did not make any corporate political donations.

BeiGene has assigned responsibility for climate related issues at the Board level through the Board's participation in the Responsible Business & Sustainability (RB&S) Working Group. In early 2023, the working group reviewed and approved BeiGene's climate risk assessment and strategy and, later in the year, approved the first quantitative emissions Scope 1 and 2 reduction target. This has set the tone from the top regarding BeiGene's commitment to addressing its impact on the environment, as well as the risks and opportunities the company faces due to climate change. BeiGene also regularly reviews compliance with current sustainability-related regulations and disclosure requirements and keeps abreast of changing reporting expectations and mandates, particularly those forthcoming in Europe. A concise compendium and summary of new and upcoming climate-related regulations focusing on key markets were shared with the RB&S Working Group in Q1 2024. We recognize the need for more robust policies and regulations aimed at reducing greenhouse gas emissions, water pollution, and other environmental impacts at the local, national, and international levels, and we view them as an opportunity to strengthen our policies and practices to further advance our climate-related progress. For more information on our RB&S Working Group, please see Responsible Business & Sustainability Governance, page 51.

###### Our Climate Governance

BeiGene has assigned responsibility for climate related issues at the Board level through the Board's participation in the Responsible Business & Sustainability (RB&S) Working Group. In early 2023, the working group reviewed and approved BeiGene's climate risk assessment and strategy and, later in the year, approved the first quantitative emissions Scope 1 and 2 reduction target. This has set the tone from the top regarding BeiGene's commitment to addressing its impact on the environment, as well as the risks and opportunities the company faces due to climate change.

BeiGene also regularly reviews compliance with current sustainability-related regulations and disclosure requirements and keeps abreast of changing reporting expectations and mandates, particularly those forthcoming in Europe. A concise compendium and summary of new and upcoming climate-related regulations focusing on key markets were shared with the RB&S Working Group in Q1 2024. We recognize the need for more robust policies and regulations aimed at reducing greenhouse gas emissions, water pollution, and other environmental impacts at the local, national, and international levels, and we view them as an opportunity to strengthen our policies and practices to further advance our climate-related progress. For more information on our RB&S Working Group, please see Responsible Business & Sustainability Governance, page 51.

**Policy Advocacy**

BeiGene also regularly engages with policymakers in support of our mission to provide high-quality, affordable medicines to patients. We follow international governance guidelines and country-specific regulations and laws such as the Lobbying Disclosure Act in the U.S., to ensure proper interactions with government officials. In 2020, BeiGene did not make any corporate political donations.

###### Political Advocacy

BeiGene regularly engages with policymakers in support of

our mission to provide high-quality, affordable medicines to
patients. We follow international governance guidelines and
country-specific regulations and laws, such as the Lobbying
Disclosure Act in the U.S., to ensure proper interactions
with government officials. In 2022, BeiGene did not make
any corporate political donations.

###### Advocacy

BeiGene regularly engages with policymakers in support of our mission to provide high-quality, affordable medicines to patients. We follow international governance guidelines and country-specific regulations and laws, such as the Lobbying Disclosure Act in the U.S., to ensure proper interactions with government officials. In 2021, BeiGene did not make any corporate political donations.

###### Political Advocacy

BeiGene regularly engages with policymakers in support of

our mission to provide high-quality, affordable medicines to
patients. We follow international governance guidelines and
country-specific regulations and laws, such as the Lobbying
Disclosure Act in the U.S., to ensure proper interactions
with government officials. In 2022, BeiGene did not make
any corporate political donations.

###### Advocacy

BeiGene regularly engages with policymakers in support of our mission to provide high-quality, affordable medicines to patients. We follow international governance guidelines and country-specific regulations and laws, such as the Lobbying Disclosure Act in the U.S., to ensure proper interactions with government officials. In 2021, BeiGene did not make any corporate political donations.